The $187.5M cash sale of the PRV provides a significant non-dilutive capital boost, strengthening Ascendis's balance sheet and extending its cash runway. Traders should watch for potential use of proceeds (e.g., pipeline investment, debt reduction) in upcoming filings and monitor for any related guidance updates.
Price Chart
Executive Summary
Ascendis Pharma completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cash to an undisclosed buyer. The PRV was awarded by the FDA upon approval of YUVIWEL (navepegritide) in February 2026. This non-dilutive cash infusion provides a significant capital boost for the company's operations.
Key Facts
- Sale of Rare Pediatric Disease Priority Review Voucher (PRV) completed on June 17, 2026
- Proceeds of $187.5 million in cash, before transaction-related expenses
- PRV was awarded by FDA upon approval of YUVIWEL (navepegritide) in February 2026
- Buyer is undisclosed
- Cash infusion is non-dilutive to shareholders
Financial Impact
$187.5 million cash infusion
Risk Factors
- Proceeds are before transaction-related expenses; net amount may be slightly lower
- No specific use of proceeds disclosed yet
- Historical performance shows negative T+20 alpha for this ticker
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-274306 |
| Document: 0001193125-26-274306-index-headers.html | 0001193125-26-274306 |
| Document: 0001193125-26-274306-index.html | 0001193125-26-274306 |
| Document: 0001193125-26-274306.txt | 0001193125-26-274306 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access